EGFR and non-small cell lung carcinoma: Besides, clinical trials like DZD9008 and CLN-081 against EGFR exon 20 insertion–positive NSCLC are ongoing (James Chih-Hsin Yang, 2021; Zofia Piotrowska, 2021).